Verastem, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VSTM | OLMA | 2410.HK | SNDX | AVBP | ERAS | |
|---|---|---|---|---|---|---|
| Market cap | 1.20B | 659.73M | 1.21B | 940.80M | 665.16M | 5.21B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -8.1 | -2.9 | -6.1 | -14.4 | -3.6 | -23.9 |
| Price/book | 17.8 | 1.5 | 4.0 | -54.7 | 1.8 | 12.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +19.73% | −7.55% | −80.24% | −28.86% | −28.97% | +565.63% |
| Today | +0.82% | +2.59% | +9.61% | −26.87% | +3.61% | +1.84% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VSTM news ›Veralto Corp Jumps As VLTO Hikes 2026 EPS Outlook
Veralto Corp stocks have been trading up by 6.77 percent after strong earnings beat expectations and boosted investor confidence. What Traders Need To Know Q3 results topped expectations with adjusted EPS at $1.18 versus $1.09 views and…
Wedbush Sticks to Their Hold Rating for Vera Therapeutics (VERA)
Wedbush analyst Laura Chico maintained a Hold rating on Vera Therapeutics today and set a price target of $34.00. Chico covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Vera Therapeutics, and Biogen.…
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics, with a price target of $76.00. Divan covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Jade Biosciences, and…
Vera Therapeutics (VERA) Receives a Buy from Cantor Fitzgerald
In a report released today, Pete Stavropoulos from Cantor Fitzgerald maintained a Buy rating on Vera Therapeutics, with a price target of $100.00. Stavropoulos covers the Healthcare sector, focusing on stocks such as Vera Therapeutics,…
Verano Holdings remains undervalued, this analyst says
On Oct. 29, Haywood Securities analyst Neal Gilmer maintained his “Buy” rating and C$18.75 target on Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) following third-quarter results that fell short…
Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says
Vera Therapeutics priced its newly approved Trutakna at about $425,000 annually, above Wedbush's expectations, as the drug is expected to become available within three to four weeks, the brokerage... Biotechnology & Medical Research Vera…
Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target
Vera Therapeutics has an average rating of buy and mean price target of $77.07, according to analysts polled by FactSet. ... Biotechnology & Medical Research Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price…
Analyzing Verastem (NASDAQ:VSTM) and Roivant Sciences (NASDAQ:ROIV)
Posted by Defense World Staff on Oct 25th, 2026 Verastem (NASDAQ:VSTM – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
Verastem Consensus Price Target Increased by 17.42% to $17.57
October 23, 2026 — 06:28 am EDT Written by George Maybach for Fintel The average one-year price target for Verastem (NASDAQCM:VSTM) (DB:2VSA) has been revised to $17.57 / share. This is an increase of 17.42% from the prior estimate of…
Verastem (NASDAQ:VSTM) Stock Price Up 8% – Time to Buy?
Posted by Michael Walen on Oct 22nd, 2026 Verastem, Inc. (NASDAQ:VSTM – Get Free Report)’s share price traded up 8% during mid-day trading on Thursday. The company traded as high as $9.89 and last traded at $9.9440. 3,140,326 shares traded…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- stocktitan.net6
- tradingview.com5
- defenseworld.net3
- themarketsdaily.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 44 articles, not a forecast.